Kye Pharmaceuticals Appoints Veteran Financial Leader Geri-Lynn Kushneryk as Chief Financial Officer
MISSISSAUGA, ON — August 23, 2026 — Kye Pharmaceuticals Inc., a rapidly growing Canadian specialty pharmaceutical company, today announced the appointment of Geri-Lynn Kushneryk, CPA, CA, as its new Chief Financial Officer (CFO). In this executive role, Ms. Kushneryk will lead the company's consolidated financial strategy, corporate development, and administrative functions to support Kye’s accelerating growth and expanding commercial pipeline.
Ms. Kushneryk brings over two decades of highly specialized financial leadership across the pharmaceutical, healthcare, technology, and private equity sectors. She most recently served as CFO at Searchlight Pharma Inc. from 2021 to 2025, where she drove exponential financial expansion, leading the company from a venture backed early-stagethrough two acquisitions, culminating in a successful sale to Apotex in May 2025 of over CAD$500 million.
"We are thrilled to welcome Geri-Lynn to our executive leadership team at this pivotal moment in Kye's trajectory," said John McKendry, President of Kye Pharmaceuticals. "Her outstanding track record of scaling businesses, negotiating complex capital structures, and leading successful corporate integrations aligns perfectly with our strategic goals. Geri-Lynn’s financial expertise in the Canadian pharmaceutical market will be instrumental as we expand our commercial footprint and bring vital, innovative treatments to Canadian patients."
Throughout her career, Ms. Kushneryk has established a reputation as a solution-oriented, analytical strategist skilled at building automated reporting frameworks, setting up and optimizing supply chain, and managing complex cross-border restructurings. Her executive background includes serving as CFO for Drakkar and Partners Inc., Gurus Solutions Inc., and Pleio Health Support Systems Inc., as well as managing a venture investment portfolio as Investment Director for the Caisse de dépôt et placement du Québec following her foundational years at PricewaterhouseCoopers.
"Kye Pharmaceuticals has built incredible momentum by targeting critical unmet clinical needs with agility and efficiency," said Ms. Kushneryk. "I am excited to join this entrepreneurial team and look forward to setting the company up for rapid growth by building out our financial infrastructure and aligning our financial objectives to this end."
Ms. Kushneryk holds a Graduate Diploma in Public Accountancy from Concordia University and a Bachelor of Arts from McGill University.
About Kye Pharmaceuticals
Kye Pharmaceuticals Inc. is a private, growth-stage specialty pharmaceutical company based in Mississauga, Ontario. Kye is dedicated to improving the lives of Canadian patients by identifying, licensing, registering, and commercializing innovative prescription medicines that satisfy major unmet clinical needs. Kye's growing pipeline spans critical therapeutic areas, including ADHD, cardiology, rare diseases, and neurology. For more information, visit kyepharma.com.
